Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 25;66(39-3):7838-7849.
doi: 10.1016/j.tet.2010.07.037.

An efficient and versatile synthesis of GlcNAcstatins-potent and selective O-GlcNAcase inhibitors built on the tetrahydroimidazo[1,2-a]pyridine scaffold

Affiliations

An efficient and versatile synthesis of GlcNAcstatins-potent and selective O-GlcNAcase inhibitors built on the tetrahydroimidazo[1,2-a]pyridine scaffold

Vladimir S Borodkin et al. Tetrahedron. .

Abstract

We report a novel approach to the synthesis of GlcNAcstatins-members of an emerging family of potent and selective inhibitors of peptidyl O-GlcNAc hydrolase build upon tetrahydroimidazo[1,2-a]pyridine scaffold. Making use of a streamlined synthetic sequence featuring de novo synthesis of imidazoles from glyoxal, ammonia and aldehydes, a properly functionalised linear GlcNAcstatin precursor has been efficiently prepared starting from methyl 3,4-O-(2',3'-dimethoxybutane-2',3'-diyl)-α-d-mannopyranoside. Subsequent ring closure of the linear precursor in an intramolecular S(N)2 process furnished the key fused d-mannose-imidazole GlcNAcstatin precursor in excellent yield. Finally, a sequence of transformations of this key intermediate granted expeditious access to a variety of the target compounds bearing a C(2)-phenethyl group and a range of N(8) acyl substituents. The versatility of the new approach stems from an appropriate choice of a set of acid labile permanent protecting groups on the monosaccharide starting material. Application was demonstrated by the synthesis of GlcNAcstatins containing polyunsaturated and thiol-containing amido substituents.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Figure 2
Figure 2
Scheme 1
Scheme 1
Scheme 2
Scheme 2
Reagents and conditions: (i) PMBCl, NaH, n-Bu4NI, DMF, rt, 16 h, 50%; (ii) I2, ImH, PPh3, toluene, 70 °C, 3 h, 75%; (iii) H2, Pd/C, MeOH/EtOAc, 3 h, 50%; (iv) (a) Zn, THF/H2O (10:1), 65 °C, 1 h, (b) 40% aqueous glyoxal, 7 M NH3/MeOH, 0–70 °C, 2 h, 70%.
Scheme 3
Scheme 3
Reagents and conditions: (i) (a) K2(OsO4)/K3[Fe(CN)6], K2CO3, CH3SO2NH2, t-BuOH/THF/water, rt, 24 h, (b) TIPSCl, Py, 50 °C, 16 h, 78%; (ii) Tf2O, pyridine, −15 °C tort, 1 h, 92%; (iii) (a) (COCl)2, DMSO, DCM, −60 °C then Et3N, (b) NaBH4, EtOH, rt, 16 h, 80%; (iv) Tf2O, Py, C2H4Cl2, −15 °C then 50 °C, 3 h, 90%.
Scheme 4
Scheme 4
Reagents and conditions: (i) NIS 2.5 equiv, MeCN, 6 h, rt, 95%; (ii) Tf2O, Py, C2H4Cl2, −15 °C then 50 °C; (iii) NIS 10 equiv, DMF, 85 °C, 36 h, 80% or NIS 3 equiv, MeCN, PPTS, 80 °C, 3 h, 65%; (iv) EtMgBr, THF, 0 °C, 10 min, 88%.
Scheme 5
Scheme 5
Reagents and conditions: (i) NIS 3 equiv, MeCN, 6 h, rt, 78%.
Scheme 6
Scheme 6
Reagents and conditions: (i) PhCCH, CuI, Et3N, Pd(PPh3)4, DMF, 80 °C, 16 h, 93%; (ii) DDQ, DCM/H2O, 4 h, 83%; (iii) DPPA, DBU, toluene, rt then 80 °C, 2 h, 93%; (iv) (a) H2, Pd/C, MeOH or EtOAc, 1 h (b) (RCO)2O, Et3N, DCM for 2931 or PyBOP, DIPEA, RCO2H, DCM, rt, 16 h, for 3234; (v) TFA/H2O (95:5), rt, 36 h, 60–80%; (vi) DMF, MeONa/MeOH, DTT, 2 h, 56%.

Similar articles

Cited by

References

    1. Torres C.R., Hart G.W. J. Biol. Chem. 1984;259:3308–3317. - PubMed
    1. Zachara N.E., Hart G.W. Biochim. Biophys. Acta. 2004;1673:13–28. - PubMed
    1. Love D.C., Hanover J.A. Sci. STKE. 2005;312:1–14. - PubMed
    1. Wells L., Gao Y., Mahoney J.A., Vosseller K., Chen C., Rosen A., Hart G.W. J. Biol. Chem. 2002;277:1755–1761. - PubMed
    1. Lehman D.M., Fu D.J., Freeman A.B., Hunt K.J., Leach R.J., Johnson-Pais T., HamLington J., Dyer T.D., Arya R., Abboud H., Goring H.H., Duggirala R., Blangero J., Konrad R.J., Stern M.P. Diabetes. 2005;54:1214–1221. - PubMed

LinkOut - more resources